Verrica Pharmaceuticals’ (VRCA) Buy Rating Reaffirmed at HC Wainwright

Verrica Pharmaceuticals (NASDAQ:VRCA)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 98.02% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Zacks Research upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Verrica Pharmaceuticals has an average rating of “Hold” and an average target price of $14.50.

Verrica Pharmaceuticals Price Performance

Verrica Pharmaceuticals stock opened at $6.06 on Tuesday. Verrica Pharmaceuticals has a 52 week low of $3.28 and a 52 week high of $9.82. The company has a quick ratio of 1.98, a current ratio of 2.10 and a debt-to-equity ratio of 0.03. The firm’s 50-day simple moving average is $6.09 and its 200 day simple moving average is $6.45. The firm has a market capitalization of $104.11 million, a PE ratio of -5.88 and a beta of 1.54.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.18. Verrica Pharmaceuticals had a negative net margin of 47.97% and a negative return on equity of 1,077.78%. The business had revenue of $5.02 million for the quarter, compared to analyst estimates of $4.51 million. On average, equities research analysts predict that Verrica Pharmaceuticals will post -1.84 EPS for the current fiscal year.

Institutional Trading of Verrica Pharmaceuticals

Several large investors have recently bought and sold shares of the company. State Street Corp boosted its stake in shares of Verrica Pharmaceuticals by 14.1% during the 4th quarter. State Street Corp now owns 23,481 shares of the company’s stock valued at $195,000 after buying an additional 2,900 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Verrica Pharmaceuticals by 22.6% during the 1st quarter. Renaissance Technologies LLC now owns 32,360 shares of the company’s stock valued at $171,000 after buying an additional 5,960 shares during the last quarter. Man Group plc purchased a new position in shares of Verrica Pharmaceuticals during the 4th quarter valued at approximately $94,000. Quadrature Capital Ltd purchased a new position in shares of Verrica Pharmaceuticals during the 4th quarter valued at approximately $99,000. Finally, Beck Mack & Oliver LLC purchased a new position in shares of Verrica Pharmaceuticals during the 4th quarter valued at approximately $100,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.